Abstract:Purpose of review: Type 1 diabetes (T1D) occurs when there is destruction of beta cells within the islets of Langerhans in the pancreas due to autoimmunity. It is considered a complex disease, and different complications can surface and worsen the condition if T1D is not managed well. Since it is an incurable disease, numerous treatments and therapies have been postulated in order to control T1D by balancing hyperglycemia control while minimizing hypoglycemic episodes. The purpose of this review is to primarily look into the current state of the available immunological therapies and their advantages for the treatment of T1D. Recent findings: Over the years, immunological therapy has become the center of attraction to treat T1D. Immunomodulatory approaches on non-antigens involving agents such as cyclosporine A, mycophenolate mofetil, anti-CD20, cytotoxic T cells, anti-TNF, anti-CD3, and anti-thymocyte globulin as well as immunomodulative approaches on antigens such as insulin, glutamic acid decarboxylase, and heat shock protein 60 have been studied. Aside from these two approaches, studies and trials have also been conducted on regulatory T cells, dendritic cells, interleukin 2, interleukin 4, M2 macrophages, and rapamycin/interleukin 2 combination therapy to test their effects on patients with T1D. Many of these agents have successfully suppressed T1D in non-obese diabetic (NOD) mice and in human trials. However, some have shown negative results. To date, the insights into the management of the immune system have been increasing rapidly to search for potential therapies and treatments for T1D. Nevertheless, some of the challenges are still inevitable. A lot of work and effort need to be put into the investigation on T1D through immunological therapy, particularly to reduce complications to improve and enhance clinical outcomes.

Asymmetric facilitation from repeated paired magnetic stimulation of human motor cortex

Interleukin-35: A key player managing pre-diabetes and chronic inflammatory type 1 autoimmune diabetes

The potential therapeutic role of IL-35 in pathophysiological processes in type 1 diabetes mellitus

Immunomodulation of Interleukin-34 and Its Potential Significance As a Disease Biomarker and Therapeutic Target

Research progresses of IL-35 in autoimmune diseases

Interleukin-1 Receptor Antagonist: A New Therapy for Type 2 Diabetes Mellitus

Interleukin-1 Receptor Antagonist Improves Normoglycemia and Insulin Sensitivity in Diabetic Goto-Kakizaki-Rats

Sustained Delivery Of Il-1ra From Pf127-Gel Reduces Hyperglycemia In Diabetic Gk-Rats

Current Status on Immunological Therapies for Type 1 Diabetes Mellitus

The immunology of type 1 diabetes

Current perspectives and the future of disease-modifying therapies in type 1 diabetes

Effects of temporal delays on the ear asymmetry in dichotic listening.

Immunoprotection of Cellular Transplants for Autoimmune Type 1 Diabetes through Local Drug Delivery

Recent advances in immune checkpoint inhibitor-induced type 1 diabetes mellitus

Persistent IL-2 Receptor Signaling by IL-2/CD25 Fusion Protein Controls Diabetes in NOD Mice by Multiple Mechanisms

Immunotherapy-Based Strategies for Treatment of Type 1 Diabetes

Immune Checkpoint Inhibitor-Induced Diabetes Mellitus: Potential Role of T Cells in the Underlying Mechanism

Interleukin-35: the future of hyperimmune-related diseases?

Regulatory T cell-based therapy in type 1 diabetes: Latest breakthroughs and evidence

Harnessing cellular therapeutics for type 1 diabetes mellitus: progress, challenges, and the road ahead

Mechanisms and therapeutic strategies of immune checkpoint molecules and regulators in type 1 diabetes